LEAD-472

LEAD-472 is a bispecific antibody drug candidate in the discovery stage, developed by LeadArtis. It is designed to function as a tumor necrosis factor receptor (TNFR) agonist and tumor-associated antigen (TAA) inhibitor, with additional activity as an antibody-dependent cell-mediated cytotoxicity (ADCC) agent and T lymphocyte stimulant. The drug targets both TNFR and TAA, aiming to stimulate immune responses against cancer cells through multiple mechanisms including direct activation of immune effector cells and inhibition of tumor-associated antigens. Its primary therapeutic focus is on oncology indications such as breast cancer, lung cancer, ovarian epithelial carcinoma, pancreatic cancer, testicular neoplasms, and thyroid cancer[1][3].